Abstract:A successful treatment of AIDS world-wide is severely hindered by the HIV virus' drug resistance capability resulting from complicated mutation patterns of viral proteins. Such a system of mutations enables the virus to survive and reproduce despite the presence of various antiretroviral drugs by disrupting their binding capability. Although these interacting mutation patterns are extremely difficult to efficiently uncover and interpret, they contribute valuable information to personalized therapeutic regimen design. The use of Bayesian statistical modeling provides an unprecedented opportunity in the field of anti-HIV therapy to understand detailed interaction structures of drug resistant mutations. Multiple Bayesian models equipped with Markov Chain Monte Carlo (MCMC) methods have been recently proposed in this field (Zhang et al. in PNAS 107: 1321, 2010 [1]; Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]; Svicher et al. in Antiviral Res 93(1): 86-93, 2012 [3]; Svicher et al. in Antiviral Therapy 16(7): 1035-1045, 2011 [4]; Svicher et al. in Antiviral Ther 16(4): A14-A14, 2011 [5]; Svicher et al. in Antiviral Ther 16(4): A85-A85, 2011 [6]; Alteri et al. in Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-Terminus, 2011 [7]). Probabilistically modeling mutations in the HIV-1 protease or reverse transcriptase (RT) isolated from drug-treated patients provides a powerful statistical procedure that first detects mutation combinations associated with single or multiple-drug resistance, and then infers detailed dependence structures among the interacting mutations in viral proteins (Zhang et al. in PNAS 107: 1321, 2010 [1]; Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]). Combined with molecular dynamics simulations and free energy calculations, Bayesian analysis predictions help to uncover genetic and structural mechanisms in the HIV treatment resistance. Results obtained with such stochastic methods pave the way not only for optimization of the use for existing HIV drugs, but also for the development of the new more efficient antiretroviral medicines. In this chapter we survey current challenges in the bioinformatics of anti-HIV therapy, and outline how recently emerged Bayesian methods can help with the clinical management of HIV-1 infection. We will provide a rigorous review of the Bayesian variable partition model and the recursive model selection procedure based on probability theory and mathematical data analysis techniques while highlighting real applications in HIV and HBV studies including HIV drug resistance (Zhang et al. in PNAS 107: 1321, 2010 [1]), cross-resistance (Zhang et al. in J Proteome Sci Comput Biol 1: 2, 2012 [2]), HIV coreceptor usage (Svicher et al. in Antiviral Therapy 16(7): 1035-1045, 2011 [4]; Svicher et al. in Antiviral Ther 16(4): A14-A14, 2011 [5]; Alteri et al. in Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-Terminus, 2011 [7]), and occult HBV infection (Svicher et al. in Antiviral Res 93(1): 86-93, 2012 [3]; Svicher et al. in Antiviral Ther 16(4): A85-A85, 2011 [6]).

A Mutagenetic Tree Hidden Markov Model for Longitudinal Clonal HIV Sequence Data

Intrapatient Evolutionary Dynamics in an Individual Infected with HIV-1 CRF01_AE Who Experienced Periods of Treatment Failure

Modeling Drug Resistance Emergence and Transmission in HIV-1 in the UK

Using A Mutual Information-Based Site Transition Network to Map the Genetic Evolution of Influenza A/H3n2 Virus

Bayesian analysis of complex interacting mutations in HIV drug resistance and cross-resistance.

Identification of HIV Rapid Mutations Using Differences in Nucleotide Distribution over Time.

Recombination Rate and Selection Strength in HIV Intra-patient Evolution

Detecting and Understanding Combinatorial Mutation Patterns Responsible for HIV Drug Resistance

Simulating within host human immunodeficiency virus 1 genome evolution in the persistent reservoir

Simulating Genomes and Populations in the Mutation Space: An example with the evolution of HIV drug resistance

Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy's outcome for HIV-1

Mathematical Analysis of the Probability of Spontaneous Mutations in HIV-1 Genome and Their Role in the Emergence of Resistance to Anti-Retroviral Therapy

Mathematical modelling of the within-host HIV quasispecies dynamics in response to antiviral treatment

Inferring Transmission Heterogeneity Using Virus Genealogies: Estimation and Targeted Prevention.

A comprehensive stochastic computational model of HIV infection from DNA integration to viral burst

Identifying Selections Operating on HIV-1 Reverse Transcriptase via Uniform Manifold Approximation and Projection

Large Evolutionary Rate Heterogeneity among and within HIV-1 Subtypes and CRFs

Reliable reconstruction of HIV-1 whole genome haplotypes reveals clonal interference and genetic hitchhiking among immune escape variants

Genetic interactions shaping evolutionary trajectories in an RNA virus population

Longitudinal analysis for predicting amino acid changes in HIV-1 using association rule mining

Parametric inference of recombination in HIV genomes